Thoughts and suggestions on the fact that dacomitinib reduction did not affect its efficacy in the Archer 1050 study

Future OncologyVol. 18, No. 7 EditorialThoughts and suggestions on the fact that dacomitinib reduction did not affect its efficacy in the Archer 1050 studyJing Zhang, Yue Ren, Qiu Wang & Yu-Ming JiaJing ZhangDepartment of Oncology, The Second People's Hospital of Yibin, No. 268, Nanguang Road, Yibin, 644000, Sichuan Province, China, Yue RenDepartment of Oncology, Yangzhou University, No. 136, Jiangyang Middle Road, Yangzhou, 225002, Jiangsu Province, China, Qiu WangDepartment of Oncology, The Second People's Hospital of Yibin, No. 268, Nanguang Road, Yibin, 644000, Sichuan Province, China & Yu-Ming Jia *Author for correspondence: E-mail Address: ybjqx3340@sina.comhttps://orcid.org/0000-0002-3934-9133Department of Oncology, The Second People's Hospital of Yibin, No. 268, Nanguang Road, Yibin, 644000, Sichuan Province, ChinaPublished Online:20 Jan 2022https://doi.org/10.2217/fon-2021-0983AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: adverse reactionsdacomitinibefficacypharmacokineticsplasma exposure concentrationside effectsReferences1. Corral J, Mok TS, Nakagawa K et al. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 15(24), 2795–2805 (2019).Link, CAS, Google Scholar2. Wu YL, Cheng Y, Zhou X et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 8(11), 1454–1514 (2017).Crossref, Google Scholar3. Mok TS, Cheng Y, Zhou X et al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. Drugs 81(2), 257–266 (2021).Crossref, Medline, CAS, Google Scholar4. Nishio M, Kato T, Niho S et al. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer Sci. 111(5), 1724–1738 (2020).Crossref, Medline, CAS, Google Scholar5. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15(2), 213–222 (2014).Crossref, Medline, CAS, Google Scholar6. Zhou Q, Wu YL, Corral J et al. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncol. 15(13), 1481–1491 (2019).Link, CAS, Google Scholar7. Liu K, Fang N, Niu L et al. Initial low dose of dacomitinib for first-line treatment of patients with EGFR exon 21 mutated non small cell lung cancer. J. Clin. Oncol. 39(Suppl. 15), e21083 (2021).Crossref, Google Scholar8. Tan A, Mok T, Kim D et al. P2.14-20 ATORG-003: dacomitinib with or without dose titration as first-line therapy for metastatic EGFR mutant non-small cell lung cancer. J. Thorac. Oncol. 14(Suppl. 10), S836–S837 (2019).Crossref, Google Scholar9. Fostvedt L, Nickens D, Tan W. P76.44 application of longitudinal exposure-response modelling to support dacomitinib starting dose in patients with EGFR mutation-positive NSCLC. J. Thorac. Oncol. 16(Suppl. 3), S606 (2021).Crossref, Google Scholar10. Kainis I, Syrigos N, Kopitopoulou A et al. Erlotinib-associated rash in advanced non-small cell lung cancer: relation to clinicopathological characteristics, treatment response, and survival. Oncol. Res. 26(1), 59–69 (2018).Crossref, Medline, Google Scholar11. Wang P, Tan G, Zhu M, Li W, Zhai B, Sun X. Hand–foot–skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev. Gastroenterol. Hepatol. 12(1), 1–8 (2018).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByWithdrawal of dacomitinib treatment due to absence of toxicities is not justifiedJesus Corral, Tony S Mok & Yi-Long Wu17 October 2022 | Future Oncology, Vol. 18, No. 34 Vol. 18, No. 7 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 74 times History Received 10 August 2021 Accepted 8 September 2021 Published online 20 January 2022 Published in print March 2022 Information© 2022 Future Medicine LtdKeywordsadverse reactionsdacomitinibefficacypharmacokineticsplasma exposure concentrationside effectsFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download